Replies to post #796164 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

seekazy,

Thanks for reposting to highlight this topic again 😶

Some readers on the board might not be aware of the two highly significant recent combo studies at UCLA—one completed and published in Nature Comms, and the other that’s ongoing today…

Fact ✅️:
In a 2023 article published by UCLA, they cited the DC platform technology that was published in JAMA Oncology, and then added that the vaccine is now being studied in combo with checkpoint inhibitors. They also used the name DCVax-L.



In the Nature Comms publication, Northwest Biotherapeutics, Inc is named (typo/misspelling) in the Ethics Declarations section as the owner of the license.





Additionally, Dr. Liau is there to sort out any discrepancies, so you don’t have to be concerned anymore:



⭐️ AACR Advances in Ovarian Cancer Research

⭐️ NWBO to Acquire Advent BioServices

⭐️ Recent Conference

⭐️ DCVax-L Combo PII UCLA

⭐️ DC Combo PII Roswell Park

⭐️ 10-Q Quarterly Report

⭐️ 10-K Annual Report

⭐️ NICE UK 🇬🇧 DCVax-L

⭐️ ASM June 29, 2024

⭐️ Manufacturing Technology

⭐️ NWBO Acquires Flaskworks

⭐️ Roswell Park IP Portfolio

⭐️ TLR3 agonist Ampligen (rintatolimod)

⭐️ Next Generation Dendritic Cell Treatments






⭐️Combo is King!⭐️

AI Fact-Checking

Fud Flood 🌊

[survivor1x]

You can keep saying that, but it will never come true. Those in the know, know. Autologous Tumor Lysate is DC VAX in the context of what LL and UCLA are doing.